Pros and Cons of Genus plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genus plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genus plc | - | -3.311% | 7.353% | 48.980% | 63.128% | -16.571% | -35.739% |
| Ironwood Pharmaceuticals | -2.550% | 4.795% | 12.500% | -7.273% | -27.143% | -73.689% | -69.091% |
| Novocure Ltd | -1.150% | 9.135% | 16.554% | -64.364% | -61.023% | -84.072% | -91.840% |
| Iovance Biotherapeutics Inc. | 0.650% | -0.393% | -12.191% | -74.842% | -72.809% | -71.057% | -95.462% |
Comments
Genus (OTCMKTS:GENSF) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Show more
Ratings data for GENSF provided by MarketBeat